These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31735949)

  • 21. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.
    Huntington SF; Hoag JR; Wang R; Zeidan AM; Giri S; Gore SD; Ma X; Gross CP; Davidoff AJ
    J Natl Compr Canc Netw; 2019 Oct; 17(10):1194-1202. PubMed ID: 31590152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.
    Yin H; Meng T; Shu L; Mao M; Zhou L; Chen H; Song D
    Chem Biol Drug Des; 2017 Nov; 90(5):892-899. PubMed ID: 28440948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma.
    Multani P
    Int J Hematol; 2002 Dec; 76(5):401-10. PubMed ID: 12512834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 131I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: the first case report in Thailand.
    Kositwattanarerk A; Changmuang W; Sangsuriyan J; Thongklam K; Sritara C; Utamakul C; Chamroonrat W; Thamnirat K; Anongpornyochkul Y; Chancharunee S
    J Med Assoc Thai; 2013 Jun; 96(6):756-60. PubMed ID: 23951835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].
    Emmanouilides C
    Rev Esp Med Nucl; 2006; 25(1):42-54. PubMed ID: 16540013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
    Schaefer-Cutillo J; Friedberg JW
    Semin Hematol; 2008 Apr; 45(2):110-7. PubMed ID: 18381106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma.
    Smith S; Sweetenham JW
    Future Oncol; 2007 Jun; 3(3):255-62. PubMed ID: 17547519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioimmunotherapy strategies for non-Hodgkin's lymphomas.
    Corcoran MC; Eary J; Bernstein I; Press OW
    Ann Oncol; 1997; 8 Suppl 1():133-8. PubMed ID: 9187447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
    Repetto-Llamazares AH; Larsen RH; Patzke S; Fleten KG; Didierlaurent D; Pichard A; Pouget JP; Dahle J
    PLoS One; 2015; 10(6):e0128816. PubMed ID: 26066655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.
    Gholipour N; Vakili A; Radfar E; Jalilian AR; Bahrami-Samani A; Shirvani-Arani S; Ghannadi-Maragheh M
    J Cancer Res Ther; 2013; 9(2):199-204. PubMed ID: 23771358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
    Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
    BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
    Shome D; Esmaeli B
    Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].
    Setoain X; López-Guillermo A; Ruiz A; Pons F
    Rev Esp Med Nucl; 2006; 25(1):55-68; quiz 69-70.. PubMed ID: 16540015
    [No Abstract]   [Full Text] [Related]  

  • 37. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of pretreatment ¹⁸F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using ¹³¹I-rituximab.
    Lim I; Park JY; Kang HJ; Hwang JP; Lee SS; Kim KM; Choi TH; Yang SH; Kim BI; Choi CW; Lim SM
    Acta Haematol; 2013; 130(2):74-82. PubMed ID: 23548464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
    Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
    J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Kaminski MS; Armitage JO
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-54-8. PubMed ID: 23570101
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.